Sarepta Therapeutics (NASDAQ:SRPT) had its price target trimmed by Credit Suisse Group from $207.00 to $201.00 in a report released on Tuesday, The Fly reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.
Several other research analysts also recently issued reports on the company. HC Wainwright reaffirmed a buy rating and issued a $267.00 price objective (up previously from $160.00) on shares of Sarepta Therapeutics in a research note on Tuesday. Evercore ISI reaffirmed a buy rating and issued a $200.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, August 8th. Janney Montgomery Scott lowered their price objective on Sarepta Therapeutics from $200.00 to $175.00 and set a buy rating for the company in a research note on Tuesday. William Blair reaffirmed a buy rating on shares of Sarepta Therapeutics in a research note on Friday, August 9th. Finally, Citigroup lowered their price objective on Sarepta Therapeutics from $201.00 to $190.00 and set a buy rating for the company in a research note on Thursday, May 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty-one have given a buy rating to the company’s stock. Sarepta Therapeutics has an average rating of Buy and a consensus price target of $197.78.
Sarepta Therapeutics stock opened at $93.61 on Tuesday. The business has a 50 day moving average of $139.42 and a 200-day moving average of $130.16. Sarepta Therapeutics has a 1 year low of $90.24 and a 1 year high of $165.87. The company has a debt-to-equity ratio of 0.44, a current ratio of 8.81 and a quick ratio of 7.84. The company has a market capitalization of $6.96 billion, a P/E ratio of -17.14 and a beta of 2.01.
In related news, Director Richard Barry acquired 5,000 shares of Sarepta Therapeutics stock in a transaction dated Tuesday, August 20th. The stock was bought at an average price of $99.32 per share, with a total value of $496,600.00. Following the transaction, the director now directly owns 3,182,065 shares in the company, valued at approximately $316,042,695.80. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Douglas S. Ingram acquired 16,252 shares of Sarepta Therapeutics stock in a transaction dated Monday, August 12th. The shares were bought at an average cost of $123.07 per share, with a total value of $2,000,133.64. Following the transaction, the chief executive officer now owns 424,405 shares in the company, valued at $52,231,523.35. The disclosure for this purchase can be found here. Insiders have acquired a total of 26,252 shares of company stock valued at $3,109,234 in the last three months. Insiders own 6.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in SRPT. Evolution Wealth Advisors LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $25,000. Trust Co. of Vermont grew its position in shares of Sarepta Therapeutics by 2,125.0% during the 2nd quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock worth $27,000 after buying an additional 170 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $32,000. Lindbrook Capital LLC acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $35,000. Finally, Quadrant Capital Group LLC acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $51,000. 93.59% of the stock is owned by institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Featured Article: Municipal Bonds
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.